Pharmacy Profiles to provide credential verification services for McKesson's Health Mart pharmacies
MCKWASHINGTON, Aug. 8, 2025 /PRNewswire/ -- Pharmacy Profiles, the trusted source for pharmacist identity and credentialing services, today announced a new agreement with McKesson Corporation to provide credential verification services for McKesson's Health Mart independent pharmacy network....
McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance
MCKIRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and ar
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $770
MCKMcKesson to Host Investor Day on September 23, 2025
MCKIRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson’s leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company’s strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along wit
Mckesson Raises FY26 Adj EPS Guidance To $36.90 - $37.70 From Prior Range Of $36.75 - $37.55
MCKMcKesson Updates FY 2026 Guidance: Raises Adjusted EPS Outlook To $36.90–$37.70, Reaffirms Full-Year Tax Rate Of 17%–19% and All Other May 8 Forecasts
MCKWells Fargo Maintains Equal-Weight on McKesson, Raises Price Target to $766
MCKHere's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years
MCKHere's How Much $100 Invested In McKesson 15 Years Ago Would Be Worth Today
MCKWhat Does the Market Think About McKesson?
MCKB of A Securities Maintains Buy on McKesson, Raises Price Target to $800
MCKMcKesson Sees FY2026 Adj EPS $36.75-$37.55 vs $36.76 Est
MCKMcKesson Q4 Adj. EPS $10.12 Beats $9.82 Estimate, Sales $90.82B Miss $94.30B Estimate
MCKMcKesson Unusual Options Activity
MCKHow To Earn $500 A Month From McKesson Stock Ahead Of Q4 Earnings
MCKMcKesson Corporation (NYSE: MCK) will release Q4 financial results after closing bell on Thursday. Analysts expect earnings at $9.83 per share and revenue of $94.2B.
UBS Maintains Buy on McKesson, Raises Price Target to $805
MCKMcKesson Shares Rise Nearly 1% After Key Signal
MCKA significant trading signal occurred for McKesson, as it demonstrated a Power Inflow at $687.38, after which MCK rose up to 0.8%.
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
MCKB of A Securities Maintains Buy on McKesson, Raises Price Target to $755
MCKSit Out The Crash With These 5 Dividend Stocks
MCKMizuho Maintains Neutral on McKesson, Raises Price Target to $690
MCKMcKesson Shares Up Over 2% After Key Signal
MCKMcKesson shares demonstrated a Power Inflow at $681.16, signaling a possible entry for traders, after which MCK rose up to 2.1%.
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $745
MCKMcKesson Corporation Acquires An Approximate 80% Controlling Interest In PRISM Vision Holdings For ~$850M
MCKSmart Money Is Betting Big In MCK Options
MCKWhat's Driving the Market Sentiment Around McKesson?
MCKIf You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
MCKWells Fargo Maintains Equal-Weight on McKesson, Raises Price Target to $691
MCKHere's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
MCKHere's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
MCKPeering Into McKesson's Recent Short Interest
MCKHere's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years
MCKCitigroup Maintains Buy on McKesson, Lowers Price Target to $677
MCKInspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And β-Thalassemia
MCKCORRECTION: McKesson Raises FY25 Adj EPS From $31.75-$32.55 To $32.40-$33.00 Vs $31.99 Est.
MCKMcKesson Sees FY25 Adj EPS $32.40-$33.00 Vs $31.75-$32.55 Est
MCKMcKesson Q2 2025 Adj EPS $7.07 Beats $6.88 Estimate, Sales $93.70B Beat $89.33B Estimate
MCKIf You Invested $1000 In This Stock 20 Years Ago, You Would Have $18,000 Today
MCKCheck Out What Whales Are Doing With MCK
MCKWhere McKesson Stands With Analysts
MCKAnalysts have provided the following ratings for McKesson (NYSE:MCK) within the last quarter:
Argus Research Maintains Buy on McKesson, Raises Price Target to $430
MCKTrump Ally Dr. Oz Hyped Unapproved 'Covid Cures' From Companies He Owns Shares Of
MCKRepublican Pennsylvania Senate candidate Dr. Mehmet Oz owns shares of two companies he publicly supported, touting their drugs as potential Covid-19 treatments — even though the drugs weren't approved by the U.S. Food and Drug Administration (FDA).
